G4 Network
Parkinson

Center of LILLE Network Coordinator

Pr. Luc DEFEBVRE
Service de neurologie A, Hôpital R. Salengro
CHRU de Lille – 59037 Cedex
Tél. : 03.20. 44. 67.30
Fax : 03.20. 44. 66.80
Mail : luc.defebvre@chru-lille.fr

Local referents

Nicolas CARRIERE

Service de neurologie A, Hôpital R. Salengro
CHRU de Lille – 59037 Cedex
Tél. : 03.20. 44. 67.30
Fax : 03.20. 44. 66.80
Mail : nicolas.carriere@chru-lille.fr

ARC Réseau

Mme Valerie SANTRAINE
Valerie.santraine@chru-lille.fr
Tel : 03 20 44 59 62 ext 31897

Center of AMIENS

Local referents

Dr TIR Melissa
Neurologue
Service de Neurologie
C.H.U. Hôpital Nord place Victor Pauch
80054 Amiens Cedex 1

Tel : 03 22 66 82 40
E-mail : melissa.tir@chu-amiens.fr

TEC Stéphanie BLIN
C.H.U. Hôpital Nord place Victor Pauchet
80054 Amiens Cedex 1

Center of ROUEN

Local referents

Pr. D. MALTETE
CHU Hôpital Charles Nicolle
Département de Neurologie
1 Rue de Germont
76031 ROUEN cedex

Tel : 02.32.88.67.49.
E-mail : david.maltete@chu-rouen.fr

ARC

BERGOT Céline
CHU Hôpital Charles Nicolle
Département de Neurologie
1 Rue de Germont
76031 ROUEN cedex

Center of CAEN

Local referents

Pr. G. DEFER
CH de côte de nacre
Service de Neurologie
Avenue de la côte de Nacre
14033 CAEN Cedex 5
Tel : 02.31.06.46.21.
E-mail : defer-gi@chu-caen.fr

Local referents

Dr C THIRIEZ
CH de côte de nacre
Service de Neurologie
Avenue de la côte de Nacre
14033 CAEN Cedex 5
Tel: 02.31.06.46.21.
E-mail : thiriez-c@chu-caen.fr

ARC

Mme Rachida MAKOURI
CH de côte de nacre
Service de Neurologie
Avenue de la côte de Nacre
14033 CAEN Cedex 5
Tel: 02 31 06 33 35
E-mail :makouri-r@chu-caen.fr

Academic Protocols

PREDI-STIM

Objectives: To study the factors predictive of the quality of life after sub thalamic stimulation in Parkinson's disease
Course: 5 visits in 5 years
Inclusion Period: ongoing
Duration of study: 9 years
Principal Investigator: Prof. D. Devos
Associated Center : Lille-Rouen-Amiens

BUSPARK

Objectives: To demonstrate that buspirone improves LID in patients with advanced PD.
Unfolding: 7 visits including 1 phone call
Inclusion period: End of inclusion June 2019
Principal Investigator: Dr FENELON Gilles Associated Center : Lille – Rouen

EARLY PUMP

Objectives: To determine the impact on the quality of life of the Apomorphine pump (APO group), compared to the optimized conventional oral treatment (BMT group), at an early stage of Parkinson's disease, while motor complications are just beginning to develop.
Unfolding: 8 visits and 3 telephone calls in 12 months
inclusion period: ongoing
Principal Investigator: Dr S. Draper
Associated Centres: Lille – Caen-Amiens

TREMOR OF CHIEF

Objectives: Evaluation of the injection effect of botulinum toxin in the treatment of chief Tremor
inclusion period March 2019
Principal Investigator: Dr F Durif Associated center : Lille-Amiens

RIVA -PSP

Objectives: To study the efficacy of rivastigmine on motor and cognitive-behavioural disorders in supra-nuclear progressive palsy
unfolding: 8 visits over 28 weeks
Inclusion period in progress
Principal investigator: Pr EUSEBIO
Associated Center : Lille – Rouen-Amiens

OXYDOPA

Objectives: To evaluate the analgesic effects of OxycodoneLP and L Dopa on central neuropathic pain in patients with Parkinson's disease
Unfolding: 8 visits on 85 days
Inclusion period : 8 weeks
Duration of study: End of inclusions April 2019
Principal Investigator: Dr BREFEL Christine

Associated center : Lille -Amiens-Rouen

DOPS-AMS

Objectives: Long-term effects of L-ThreoDOPS (3 months) on orthostatic hypotension and some non-motor symptoms in multisystem atrophy (MSA).
Unfolding : 6 visits, 5 phone calls
Inclusion period: In the process of inclusion
Principal Investigator: Dr PAVY Anne
Associated Center : Lille – Rouen

NOISE

Objectives : Study of the efficacy of N-acetylcysteine (NAC) on impulse control Disorders (ICD) induced by dopamine treatments in Parkinson disease

Unfolding : 4 visits and 2 phone call
Inclusion period: in progress
Principal Investigator: Dr M Tir
Associated Center : Lille –Rouen –Caen-Amiens

ACTIFPARK

Study to come

DOLHYPARK

PIMPARK

3PDQ

ASPIRE

Industriels Protocols

PXT002331-PREXTON

Objectives: Assess the safety, tolerance and pharmacokinetics of PXT002331 in patients with Parkinson's disease with motor fluctuations and levodopa induced dyskinesia.
Inclusion Period: ongoing
Duration of study : 28 days
Associated Center : Lille – Rouen

CUREPARK

Objectives:
To assess the safety and efficacy of BUMETAMIDE in patients with PD and motor flucutations and levodopa induced dyskinesias.
Inclusion Period: ongoing
Duration of study : 4 mois
Principal Investigator: Dr P DAMIER
Associated Center : Lille – CAEN

ACTIPARK

Objectives: To compare the impact of different patterns of use of actimetry measures on care consumption, after initiation of treatment with apomorphine pump in patients with PD
Course**:** 3 Visits and 3 reports of Actimetry
Inclusion Period: ongoing
Principal Investigator: Prof. D. Devos

Study to come

PREMIER RESEARCH